Shanghai Renji Hospital,Shanghai Jiaotong University,School of Medicine

Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer

- Phase 2 study demonstrates remarkable 93.3% objective response rate for lenvatinib plus tislelizumab in treating fumarate hydratase-deficient renal cell carcinoma, with 20% achieving complete response. - The novel combination therapy shows potential as a first-line treatment for FH-RCC, a rare and aggressive form of kidney cancer that typically affects young adults in their 30s and 40s. - While the study included only 17 patients, the preliminary safety profile appears manageable with 23.5% experiencing grade 3 or higher adverse events.